leadf
logo-loader
AIM:FUM

Futura Medical PLC

Receive alerts
Market:
AIM
Market Cap:
£39.3 m
Price
16.00 GBX
Change
0.00%
52 weeks high
32.25
52 weeks low
7.16

OUR STRATEGY

Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain to late stage, and then partner with major pharmaceutical partners at the optimum time to generate most value.

WHO WE ARE

Futura Medical is an innovative R&D company with a pipeline of products in late stage development. We are experts in topical formulations and transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®.

OUR TECHNOLOGY

Our core strength lies in our research and development capabilities in the field of topical formulations and transdermal delivery.

OUR PRODUCT DEVELOPMENT PIPELINE

MED3000 is a topical gel which utilises our proprietary technology DermaSys®,  developed specifically for treatment of ED.  MED3000 has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market.

TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains, bruises and soft tissue rheumatism.

A joint venture collaboration has been signed with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of cannabidiol.

CSD500 is a condom developed for use by healthy men to help maintain a firm erection whilst wearing a condom. CSD500 is a lubricated condom with a gel Zanifil®, which contains a 1% dose of Glyceryl Trinitrate (GTN) in the teat of a standard latex condom which is absorbed through the penis when the condom is used.

TIB200 is a topical 10% ibuprofen gel for pain relief that utilises Futura's DermaSys® technology. DermaSys® enables ibuprofen to be delivered rapidly and efficiently through the skin.  Local application and rapid, efficient absorption translate into a fast onset of action, and the potential for twice-daily dosing.

United Kingdom.

 

James Barder - Chief Executive

James Barder is the Group’s Chief Executive. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations and leads commercial negotiations. 

Ken James - Executive Director and Head of R&D

Ken James is the Head of R&D. He oversees the development, regulatory and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.

Angela Hildreth - Finance Director, Chief Operating Officer and Company Secretary

Angela joined the Group in February 2018. She leads the Group’s finance, HR and IT functions, inputs into commercial and financial strategy, leads the Group's compliance procedures and is a principal contact for shareholder and investor relations matters. 

John Clarke - Non-Executive Chairman

John Clarke is the Chairman of Futura Medical plc. He chairs the Nominations Committee and is a member of the Audit Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc, Kind Consumer Holdings Limited and is a senior adviser to Helios Investment Partners LLP.

Jonathan Freeman - Senior Independent Non-Executive Director

Jonathan Freeman is a Senior Independent Non-Executive Director. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also a Non-Executive Director of Braveheart Investment Group plc and of Kingswood Holdings Limited.

Futura Medical Head Office

Surrey Technology Centre
40 Occam Road
Guildford
Surrey
GU2 7YG

Telephone: +44 (0) 1483 685670
Fax:            +44 (0) 1483 685671

Email:         [email protected]

Investor relations and media

For specific Investor Relations or Media enquiries, please contact our Investor Relations Advisers

Optimum Strategic Communications
Warnford Court
29 Throgmorton Street
London
EC2N 2AT

www.optimumcomms.com

Tel:    +44 (0) 203 950 9144

Email: [email protected]

Nominated Adviser and Broker

Liberum
Ropemaker Place, Level 12
25 Ropemaker Street
London
EC2Y 9LY

Nominated Adviser and Broker

Liberum
Ropemaker Place, Level 12
25 Ropemaker Street
London
EC2Y 9LY

Shareholders holding more than 3% of the share capital of Futura were:

Last updated on 30 June 2020.

Futura Medical Head Office

Futura Medical plc
Surrey Technology Centre
40 Occam Road
Guildford
Surrey
GU2 7YG

Telephone: +44 (0) 1483 685670
Fax:            +44 (0) 1483 685671

Email:         [email protected]

                   [email protected]

Analyst Coverage

Graham Doyle

Liberum
25 Ropemaker St
London
EC2Y 9LY 

Tel: +44 (0) 203 100 2000

Lala Gregorek and Franc Gregori

Trinity Delta
80 Cheapside
London
EC2V 6EE

Tel: +44 (0) 20 3637 5042

Email: [email protected]

https://www.trinitydelta.org/companies/futura-medical/

Investor Relations

Optimum Strategic Communications
Warnford Court
29 Throgmorton Street
London
EC2N 2AT

www.optimumcomms.com

Tel: +44 (0) 203 950 9144

[email protected]

Nominated Adviser and Broker

Liberum
Ropemaker Place, Level 12
25 Ropemaker Street
London
EC2Y 9LY

Auditors

Grant Thornton 
1020 Eskdale Road
Winnersh
Wokingham
Berkshire
RG41 5TS

Registrars

Link Asset Services
The Registry
34 Beckenham Road
Beckenham
Kent
BR3 4TU

Principal Solicitors

Square One Law
Anson House, Burdon Terrace
Newcastle upon Tyne
NE2 3AE

Patent Attorneys

Withers and Rogers LLP
4 More London Riverside
London
SE1 2AU

Principal bankers

HSBC Bank
PO Box 160
12A North Street
Guildford
GU1 4AF